NASDAQ:BDSX - US09075X1081 - Common Stock
The current stock price of BDSX is 0.47 USD. In the past month the price increased by 24.17%. In the past year, price decreased by -76.02%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
CVS | CVS HEALTH CORP | 11.35 | 91.23B | ||
CI | THE CIGNA GROUP | 10.68 | 80.07B | ||
LH | LABCORP HOLDINGS INC | 18.45 | 23.21B | ||
DGX | QUEST DIAGNOSTICS INC | 19 | 20.10B | ||
FMS | FRESENIUS MEDICAL CARE-ADR | 12.45 | 14.76B | ||
BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 111.59 | 14.63B | ||
HIMS | HIMS & HERS HEALTH INC | 55.01 | 9.95B | ||
DVA | DAVITA INC | 14.2 | 9.84B | ||
GH | GUARDANT HEALTH INC | N/A | 7.92B | ||
CHE | CHEMED CORP | 20.35 | 6.63B | ||
RDNT | RADNET INC | 198.03 | 5.48B | ||
OPCH | OPTION CARE HEALTH INC | 21.18 | 4.64B |
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The company is headquartered in Louisville, Colorado and currently employs 273 full-time employees. The company went IPO on 2020-10-28. The firm develops diagnostic tests addressing clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers over five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung Nodule Risk Assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer. Biodesix also leverages the advanced Diagnostic Cortex artificial intelligence (AI) platform, to collaborate with biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.
BIODESIX INC
919 West Dillon Road
Louisville COLORADO US
Employees: 273
Phone: 13034170500
The current stock price of BDSX is 0.47 USD. The price increased by 1.08% in the last trading session.
The exchange symbol of BIODESIX INC is BDSX and it is listed on the Nasdaq exchange.
BDSX stock is listed on the Nasdaq exchange.
12 analysts have analysed BDSX and the average price target is 1.79 USD. This implies a price increase of 279.79% is expected in the next year compared to the current price of 0.47. Check the BIODESIX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BIODESIX INC (BDSX) has a market capitalization of 68.92M USD. This makes BDSX a Micro Cap stock.
BIODESIX INC (BDSX) currently has 273 employees.
BIODESIX INC (BDSX) has a support level at 0.43 and a resistance level at 0.49. Check the full technical report for a detailed analysis of BDSX support and resistance levels.
The Revenue of BIODESIX INC (BDSX) is expected to grow by 17.45% in the next year. Check the estimates tab for more information on the BDSX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BDSX does not pay a dividend.
BIODESIX INC (BDSX) will report earnings on 2025-10-30, after the market close.
BIODESIX INC (BDSX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.29).
The outstanding short interest for BIODESIX INC (BDSX) is 6.07% of its float. Check the ownership tab for more information on the BDSX short interest.
ChartMill assigns a technical rating of 4 / 10 to BDSX. When comparing the yearly performance of all stocks, BDSX is a bad performer in the overall market: 84.02% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to BDSX. BDSX has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months BDSX reported a non-GAAP Earnings per Share(EPS) of -0.29. The EPS increased by 36.96% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -46.82% | ||
ROE | -3609.67% | ||
Debt/Equity | 41.11 |
12 analysts have analysed BDSX and the average price target is 1.79 USD. This implies a price increase of 279.79% is expected in the next year compared to the current price of 0.47.
For the next year, analysts expect an EPS growth of 17.67% and a revenue growth 17.45% for BDSX